NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, February, 13th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.10. The company had revenue of $18.10 million for the quarter, compared to analyst estimates of $16.48 million. Karyopharm Therapeutics had a negative return on equity of 227.13% and a negative net margin of 488.08%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 equities research analysts have issued twelve-month target prices for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 53.9% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Media coverage about KPTI stock has trended neutral on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Karyopharm Therapeutics.

Some companies that are related to Karyopharm Therapeutics include Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), Zai Lab (ZLAB), Emergent Biosolutions (EBS), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Caladrius Biosciences (CLBS) and Clovis Oncology (CLVS).

Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (7.32%), State Street Corp (5.14%), Delphi Management Partners VIII L.L.C. (3.60%), Candriam Luxembourg S.C.A. (1.35%), Geode Capital Management LLC (1.32%) and FMR LLC (1.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, J. Goldman & Co LP, Palo Alto Investors LP, Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, UBS Group AG and FMR LLC. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was acquired by a variety of institutional investors in the last quarter, including Delphi Management Partners VIII L.L.C., Parkman Healthcare Partners LLC, Fairmount Funds Management LLC, Marshall Wace LLP, EAM Investors LLC, Renaissance Technologies LLC, California Public Employees Retirement System and EAM Global Investors LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $14.51.

Karyopharm Therapeutics has a market capitalization of $911.08 million and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]